1. Scrip
  2. >>Business
  3. >>Financing

Finance Watch: Vicebio Adds To 2024’s Mega-Round Total With $100m Series B

J&J Innovation-Backed ONL Raised $65m Series D

 
• By Mandy Jackson and Elizabeth Cairns

Private Company Edition: Vicebio plans to take a combo vaccine into Phase I with its $100m series B venture capital round. Also, Nura Bio raised $68m to boost its series A total to $141m and George Church-founded GC Therapeutics launched with $75m, among other recent VC deals.

Finance Watch Private Company
• Source: Shutterstock

London-based vaccine company Vicebio Ltd. has become the 17th company this year to raise a nine-figure series B round, according to Evaluate data. TCGX led its $100m series B venture capital round, announced on 23 September, with Goldman Sachs Alternatives, Avoro Ventures, venBio, UniQuest and founding investor Medicxi also participating.

Nura Bio Inc. also recently joined the $100m-plus VC mega-round club, revealing on 17 September that it raised $68m in...

Welcome to Scrip

Create an account to read this article

Already a subscriber?

More from Financing

In Brief: Soleno To Raise $200m To Boost Vykat XR Launch

 
• By Manas Mishra

Soleno Therapeutics will raise about $200m gross proceeds from an offering of 2.35m of its common stock to fund the commercialization of Vykat XR, which became the first drug for Prader-Willi syndrome to gain US approval on March 26.

Investors Back Nuclidium’s Next-Gen Copper-Based Radiopharmaceuticals

 
• By Andrew McConaghie

The Swiss company believes its platform can make radiopharmaceuticals easier to produce and more accessible to patients.

Finance Watch: Two New Venture Capital Funds Provide $600m For Biopharma

 
• By Mandy Jackson

Private Company Edition: Catalio raised more than $400m for its fourth health care-focused VC fund, while AN Venture Partners raised $200m for Japan and beyond. In VC financings, among a dearth of mega rounds, Neuron23’s $96.5m series D is the largest round in recent weeks.

Actithera Raises $75m To Enter Competitive FAP-Targeting Radioligand Field

 
• By Andrew McConaghie

While companies such as Eli Lilly and Roche have faced setbacks to their fibroblast activation protein-targeting oncology therapies, Actithera believes its radiopharmaceuticals platform will prove more successful.

More from Business

Takeda Prepares Ground For Oveporexton In Narcolepsy

 
• By Alaric DeArment

The drugmaker announced positive results from two Phase III trials for the drug in narcolepsy type 1 that analysts said bode well for the OX2R agonist class as a whole.

Leo Lands Another Big Pharma Pact With Boehringer Spevigo Deal

 
• By Kevin Grogan

Paying €90m upfront for rights to generalized pustular psoriasis drug.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: Merck & Co’s Verona acquisition; venture funding plummets in Q2; how Teva is expanding innovation; Apogee’s Phase II eczema win; and a look at India’s wave of licensing.